Cifarelli Christopher P, Jacobson Geraldine M
Department of Neurosurgery, West Virginia University, Morgantown, WV, United States.
Department of Radiation Oncology, West Virginia University, Morgantown, WV, United States.
Front Oncol. 2021 Nov 11;11:768168. doi: 10.3389/fonc.2021.768168. eCollection 2021.
Despite the continued controversy over defining an optimal delivery mechanism, the critical role of adjuvant radiation in the management of surgically resected primary and metastatic brain tumors remains one of the universally accepted standards in neuro-oncology. Local disease control still ranks as a significant predictor of survival in both high-grade glioma and treated intracranial metastases with radiation treatment being essential in maximizing tumor control. As with the emergence and eventual acceptance of cranial stereotactic radiosurgery (SRS) following an era dominated by traditional radiotherapy, evidence to support the use of intraoperative radiotherapy (IORT) in brain tumors requiring surgical intervention continues to accumulate. While the clinical trial strategies in treating glioblastoma with IORT involve delivery of a boost of cavitary radiation prior to the planned standard external beam radiation, the use of IORT in metastatic disease offers the potential for dose escalation to the level needed for definitive adjuvant radiation, eliminating the need for additional episodes of care while providing local control equal or superior to that achieved with SRS in a single fraction. In this review, we explore the contemporary clinical data on IORT in the treatment of brain tumors along with a discussion of the unique dosimetric and radiobiological factors inherent in IORT that could account for favorable outcome data beyond those seen in other techniques.
尽管在确定最佳放疗方式方面仍存在争议,但辅助放疗在手术切除的原发性和转移性脑肿瘤治疗中的关键作用仍是神经肿瘤学中普遍接受的标准之一。在高级别胶质瘤和接受治疗的颅内转移瘤中,局部疾病控制仍然是生存的重要预测指标,放疗对于最大限度地控制肿瘤至关重要。正如在传统放疗主导的时代之后出现并最终被接受的立体定向放射外科(SRS)一样,支持在需要手术干预的脑肿瘤中使用术中放疗(IORT)的证据也在不断积累。虽然用IORT治疗胶质母细胞瘤的临床试验策略包括在计划的标准外照射之前进行一次腔内放疗增强,但IORT在转移性疾病中的应用有可能将剂量提高到根治性辅助放疗所需的水平,无需额外的治疗疗程,同时提供与单次分割SRS相当或更优的局部控制。在这篇综述中,我们探讨了IORT治疗脑肿瘤的当代临床数据,并讨论了IORT固有的独特剂量学和放射生物学因素,这些因素可能解释了其优于其他技术的良好疗效数据。